Photopheresis now available to transplant patients

March 17, 2020

 

Texas Children’s Apheresis Program led by Dr. Poyyapakkam Srivaths has reached a milestone with the addition of a new service, photopheresis. Photopheresis is a medical treatment that causes photoactivation of white blood cells by separating them from blood, which are then exposed to a medication called 8-methoxypsoralen followed by UVA irradiation before returning the blood to the patient.

Texas Children’s is currently using this apheresis therapy for bone marrow transplant patients who are experiencing graft-versus-host disease and lung transplant patients who are undergoing organ rejection. Photopheresis is typically used when other treatments have failed.

We are the second institution in Houston to offer photopheresis, and the only program dedicated solely to pediatric patients.

“There was a tremendous multidisciplinary effort to make this happen,” said Dr. Tina Melicoff, medical director of Texas Children’s Lung Transplant team. “We are thrilled to now offer some of our transplant patients with rejection issues another treatment option through photopheresis.”

To be able to offer the service, two photopheresis machines were purchased and a core group of dedicated nurses were trained to operate it. Clinicians expect to treat about five patients a year with each patient receiving about three sessions a week for about 10 weeks. Each session lasts around two hours.

Texas Children’s recently conducted its first photopheresis treatment on a bone marrow transplant patient. The patient is expected to receive additional treatments over the next several months.

“By offering this therapy, we are offering hope to patients who already have been through so much,” said Dr. Robert Krance,” director of Texas Children’s Pediatric Bone Marrow Transplant/Stem Cell Transplant Program. “Photopheresis is a promising therapy for our patients experiencing host-versus-graft and organ rejection.”

Photopheresis is the second new extracorporeal therapy introduced in the past 20 years at Texas Children’s. The last extracorporeal therapy, Molecular Adsorbent Recirculating System, or MARS, was introduced six years ago for liver failure patients.

“MARS helped to transform our liver transplant program,” said Chief of Renal Services Dr. Michael Braun. “I am hopeful photopheresis will have a similar impact for our BMT and lung transplant patients.”